Senolytic Therapeutics (Senolytx), a biotechnology firm based in Barcelona and Boston and CataloniaBio & HealthTech member, has been awarded a Neotec grant for €250,000 from the Ministry of Economy, Industry and Competitiveness.

Senolytx is developing a new class of senolytic drugs, which eliminate damaged cells. “This area has a lot of potential and high impact, as we’re living in an increasingly aged society. For the first time, we’re treating age-related diseases by targeting cellular senescence,” explained CEO and co-founder Marc Ramis at the Longevity World Forum.

The company’s top priority for 2020 is preclinical development of its candidate for kidney fibrosis. It expects to get orphan-drug designation this year and begin the first clinical trial in 2021. Senolytic will also begin preclinical programmes focusing on several diseases associated with fibrosis and create a spin-off, CellSen Oncology, focusing exclusively on a target associated with the immune system and oncology.

In 2019, Senolytx also received €50,000 from the EIT Headstart Funding programme.

You may also be interested in:

Senolytic Therapeutics and future antiaging therapies, in the Financial Times